PODD Stock Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$230.59|
|52 Week High||US$324.81|
|52 Week Low||US$181.00|
|1 Month Change||-13.69%|
|3 Month Change||3.90%|
|1 Year Change||-16.62%|
|3 Year Change||41.61%|
|5 Year Change||313.61%|
|Change since IPO||1,344.80%|
Recent News & Updates
Insulet automated insulin delivery system Omnipod 5 gets CE mark
Insulet's (NASDAQ:PODD) Omnipod 5 automated insulin delivery system received CE mark in EU for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) which integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) system to automatically adjust insulin, the company said in a Sept. 20 press release. Insulet expects Omnipod 5 to be available in select countries starting mid-2023.
The Return Trends At Insulet (NASDAQ:PODD) Look Promising
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
|PODD||US Medical Equipment||US Market|
Return vs Industry: PODD exceeded the US Medical Equipment industry which returned -32.3% over the past year.
Return vs Market: PODD exceeded the US Market which returned -23.7% over the past year.
|PODD Average Weekly Movement||5.5%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: PODD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PODD's weekly volatility (5%) has been stable over the past year.
About the Company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.
Insulet Fundamentals Summary
|PODD fundamental statistics|
Is PODD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PODD income statement (TTM)|
|Cost of Revenue||US$376.20m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 03, 2022
|Earnings per share (EPS)||0.50|
|Net Profit Margin||2.94%|
How did PODD perform over the long term?See historical performance and comparison
Is PODD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PODD?
Other financial metrics that can be useful for relative valuation.
|What is PODD's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PODD's PS Ratio compare to its peers?
|PODD PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
IDXX IDEXX Laboratories
Price-To-Sales vs Peers: PODD is expensive based on its Price-To-Sales Ratio (13.6x) compared to the peer average (6.3x).
Price to Earnings Ratio vs Industry
How does PODD's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: PODD is expensive based on its Price-To-Sales Ratio (13.6x) compared to the US Medical Equipment industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is PODD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||13.6x|
|Fair PS Ratio||8.4x|
Price-To-Sales vs Fair Ratio: PODD is expensive based on its Price-To-Sales Ratio (13.6x) compared to the estimated Fair Price-To-Sales Ratio (8.4x).
Share Price vs Fair Value
What is the Fair Price of PODD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PODD ($230.59) is trading above our estimate of fair value ($121.69)
Significantly Below Fair Value: PODD is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Insulet forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PODD's forecast earnings growth (47.1% per year) is above the savings rate (1.9%).
Earnings vs Market: PODD's earnings (47.1% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: PODD's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PODD's revenue (15.8% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: PODD's revenue (15.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PODD's Return on Equity is forecast to be high in 3 years time (24.4%)
Discover growth companies
How has Insulet performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PODD has high quality earnings.
Growing Profit Margin: PODD became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PODD has become profitable over the past 5 years, growing earnings by 43.3% per year.
Accelerating Growth: PODD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PODD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).
Return on Equity
High ROE: PODD's Return on Equity (8.2%) is considered low.
Discover strong past performing companies
How is Insulet's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PODD's short term assets ($1.3B) exceed its short term liabilities ($279.3M).
Long Term Liabilities: PODD's short term assets ($1.3B) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: PODD's net debt to equity ratio (166.4%) is considered high.
Reducing Debt: PODD's debt to equity ratio has reduced from 519.9% to 334.2% over the past 5 years.
Debt Coverage: PODD's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: PODD's interest payments on its debt are not well covered by EBIT (1.9x coverage).
Discover healthy companies
What is Insulet current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Insulet Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Medical Equipment)||1.9%|
|Analyst forecast in 3 Years (Insulet)||0%|
Notable Dividend: Unable to evaluate PODD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PODD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PODD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PODD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PODD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Hollingshead (59 yo)
Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...
Experienced Management: PODD's management team is considered experienced (3.5 years average tenure).
Experienced Board: PODD's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PODD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|24 Aug 22||SellUS$766,296||Bret Christensen||Individual||2,900||US$264.24|
|06 Jun 22||SellUS$1,291,920||Charles Alpuche||Individual||6,000||US$215.32|
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||40,238||0.06%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Insulet Corporation's employee growth, exchange listings and data sources
- Name: Insulet Corporation
- Ticker: PODD
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$16.004b
- Shares outstanding: 69.40m
- Website: https://www.insulet.com
Number of Employees
- Insulet Corporation
- 100 Nagog Park
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PODD||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 2007|
|GOV||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2007|
|PODD *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 2007|
|P2OD34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 30 REPR 1 COM||BR||BRL||Jan 2022|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.